Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis (Q34952765)

5 August 2017

0 references

1 reference

title

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis (English)

1 reference

multidrug-resistant tuberculosis

5 August 2017

0 references

0 references

0 references

multiple drug resistance

1 reference

1 reference

1 reference

2

Sanjay Basu

1 reference

5 August 2017

Evan W Orenstein

1

1 reference

5 August 2017

N Sarita Shah

3

1 reference

5 August 2017

Jason R Andrews

4

1 reference

5 August 2017

Gerald H Friedland

5

1 reference

5 August 2017

Anthony P Moll

6

1 reference

5 August 2017

Neel R Gandhi

7

1 reference

5 August 2017

Alison P Galvani

8

1 reference

5 August 2017

1 March 2009

1 reference

Lancet Infectious Diseases

5 August 2017

1 reference

5 August 2017

9

1 reference

5 August 2017

153-161

1 reference

5 August 2017

3

1 reference

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Cost-effectiveness of treating multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

The treatment of multidrug-resistant tuberculosis in Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Programmes and principles in treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Bayesian approaches to random-effects meta-analysis: a comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

An intervention programme for the management of multidrug-resistant tuberculosis in France

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Multidrug-resistant tuberculosis management in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Comprehensive treatment of extensively drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Multidrug-resistant tuberculosis in the Czech Republic: strategy and therapeutic outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Multidrug- and extensively drug-resistant tuberculosis, Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

A nested case-control study on treatment-related risk factors for early relapse of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Promoting adherence to treatment for tuberculosis: the importance of direct observation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Directly observed therapy for treating tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Has the DOTS strategy improved case finding or treatment success? An empirical assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

HIV infection and multidrug-resistant tuberculosis: the perfect storm

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970041-6

7 January 2021

10.1016/S1473-3099(09)70041-6

Identifiers

DOI

1 reference

5 August 2017

1 reference